Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anastas Batalov

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Rheumatology International|September 30, 2023
The COVID-19 pandemic's impact on rheumatic disease patients' satisfaction with access to medical servicesAleksandar Marinkov, Rositsa Dimova, Rositsa Karalilova, et al.
Folia Medica|March 1, 2023
Rheumatoid arthritis and the proinflammatory cytokine IL-17Pavel Selimov, Rositsa Karalilova, Ljubinka Damjanovska, et al.
Folia Medica|July 16, 2020
Drug-neutralizing Antibodies against TNF-α blockers as Biomarkers of Therapy Effect EvaluationKrasimir Kraev, Mariela Geneva-Popova, Velichka Popova, et al.
Expert Opinion on Biological Therapy|April 23, 2026
Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group studyHonghu Tang, Eva Dokoupilova, Bogdan Batko, et al.
Arthritis Research & Therapy|December 21, 2024
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 studyNarendra Maharaj, Dharma Rao Uppada, Naveen Reddy, et al.
Clinical and Experimental Rheumatology|November 17, 2023
Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studieMarinella Govoni, Anastas Batalov, Dimitrios T Boumpas, et al.
Clinical Rheumatology|May 30, 2026
Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domainsStefano Di Donato, Juan José Alegre-Sancho, Anastas Batalov, et al.
Orthopedic Reviews|January 2, 2023
Prevalence of low bone mineral density at axial sites and fracture risk in Bulgarian populationElena Kirilova, Nikola Kirilov, Fabian Bischoff, et al.
Rheumatology (Oxford, England)|November 3, 2021
Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trialFrank Behrens, Philipp Sewerin, Eugenio de Miguel, et al.
BMC Rheumatology|March 15, 2025
Terminologies and definitions used to classify patients with osteoarthritis: a scoping reviewGabriel Gijon-Nogueron, Peter Balint, Anastas Batalov, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Rheumatology International|September 30, 2023
The COVID-19 pandemic's impact on rheumatic disease patients' satisfaction with access to medical servicesAleksandar Marinkov, Rositsa Dimova, Rositsa Karalilova, et al.
Folia Medica|March 1, 2023
Rheumatoid arthritis and the proinflammatory cytokine IL-17Pavel Selimov, Rositsa Karalilova, Ljubinka Damjanovska, et al.
Folia Medica|July 16, 2020
Drug-neutralizing Antibodies against TNF-α blockers as Biomarkers of Therapy Effect EvaluationKrasimir Kraev, Mariela Geneva-Popova, Velichka Popova, et al.
Expert Opinion on Biological Therapy|April 23, 2026
Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group studyHonghu Tang, Eva Dokoupilova, Bogdan Batko, et al.
Arthritis Research & Therapy|December 21, 2024
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 studyNarendra Maharaj, Dharma Rao Uppada, Naveen Reddy, et al.
Clinical and Experimental Rheumatology|November 17, 2023
Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studieMarinella Govoni, Anastas Batalov, Dimitrios T Boumpas, et al.
Clinical Rheumatology|May 30, 2026
Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domainsStefano Di Donato, Juan José Alegre-Sancho, Anastas Batalov, et al.
Orthopedic Reviews|January 2, 2023
Prevalence of low bone mineral density at axial sites and fracture risk in Bulgarian populationElena Kirilova, Nikola Kirilov, Fabian Bischoff, et al.
Rheumatology (Oxford, England)|November 3, 2021
Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trialFrank Behrens, Philipp Sewerin, Eugenio de Miguel, et al.
BMC Rheumatology|March 15, 2025
Terminologies and definitions used to classify patients with osteoarthritis: a scoping reviewGabriel Gijon-Nogueron, Peter Balint, Anastas Batalov, et al.
Pageof 6